Condition category
Circulatory System
Date applied
07/05/2012
Date assigned
19/06/2012
Last edited
14/07/2015
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
Chronic heart failure is currently the most frequent cause of hospitalization in Germany. Despite being treated with a wide range of drugs known as beta-blockers, many heart failure patients still have insufficient heart rate reduction. Heart failure patients should generally be controlled for heart rate as it is an important risk factor for cardiovascular death. The aims of this study is to observe the effects of Procoralan®, a drug that specifically reduces heart rate, on heart failure symptoms, heart rate reduction and quality of life in patients with chronic stable heart failure under daily routine. We also intend to assess how safe and tolerated this drug is.

Who can participate?
Ambulatory patients (who can walk), with no age and gender limitation, with stable chronic heart failure and resting heart rate ≥ 75 beats per minute, who have been prescribed Procoralan® before entering the study.

What does the study involve?
All patients involved in the study will be treated with Procoralan®. They will be asked to come to follow up visits after four weeks and then after another three months. During these visits a routine practice investigation will be carried out and a case report form regarding heart failure, co-medications and other diseases will be filled out by the doctor. The patients will be asked to fill out the patient quality of life questionnaire (EQ-5D) at each visit. According to heart rate reduction, the dosage of Procoralan® can be adapted at the first follow-up visit (week 4). Patients will be included in the study for four months.

What are the possible benefits and risks of participating?
There are no particular benefits or risks. The treatment given to the patient corresponds to the daily routine. Patients are free to withdraw from the study at any time without giving a particular reason.

Where is the study run from?
It is planned that the study will be carried out by approximately 1000 cardiologists and internists (practice-based or in outpatient clinics) across the Germany. There is no lead center.

When is the study starting and how long is it expected to run for?
The study starts on 19th April 2012 and lasts until 31st December 2012. The recruitment of participants runs until 31st July 2012.

Who is funding the study?
The funder and the sponsor of the study is Servier Deutschland, GmbH.

Who is the main contact?
Dr Peter Martinka
Peter.Martinka@de.netgrs.com

Trial website

Contact information

Type

Scientific

Primary contact

Dr Peter Martinka

ORCID ID

Contact details

Medical Affairs Officer
Servier Deutschland GmbH
Elsenheimerstraße 53
München
80687
Germany

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

IC4-16257-131 DEU

Study information

Scientific title

INTENSIFY: PractIcal daily effectiveNess and TolEraNce of Procoralan® in chronic SystolIc heart Failure in GermanY: An observational prospective multicentre study

Acronym

INTENSIFY

Study hypothesis

Effects of therapy with Procoralan® (Ivabradine) on heart failure symptoms and quality of life in patients with stable chronic systolic heart insufficiency under daily routine in an observational prospective multicentre trial by cardiologists, internists and general practitioners.

Ethics approval

Ethics Committee of Medical Faculty University of Heidelberg, 12/03/2012

Study design

Observational prospective multicentre open-label study

Primary study design

Observational

Secondary study design

Other

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Chronic stable systolic heart insufficiency

Intervention

Observational study to get information about therapy of chronic systolic heart insufficiency with Procoralan®; under daily routine practice by cardiologists, internists and general practitioners.

The diagnosis of angina will be confirmed by trialists at baseline. After the baseline visit, there is a visit after 4 weeks and the final visit after 4 months.

Intervention type

Drug

Phase

Not Applicable

Drug names

Procoralan® ((ivabradine)

Primary outcome measures

1. Change in heart failure symptoms and left ventricular function
2. Effects of therapy on quality of life assessed by EQ-5D
3. Effects of therapy on resting heart rate
4. Information about how Procoralan® SmPC and patients information are followed via standardised documentation of the dosage of Procoralan®, of comedications and concomitant diseases
5. Analysis of general tolerability of Procoralan® under routine conditions via standardised adverse reactions documentation and standardised documentation of therapy discontinuation
6. Analysis of unknown adverse drug reactions via standardised documentation

Secondary outcome measures

No secondary outcome measures

Overall trial start date

19/04/2012

Overall trial end date

31/12/2012

Reason abandoned

Eligibility

Participant inclusion criteria

1. Adult patients (male, female) with chronic systolic heart insufficiency
2. New York Heart Association (NYHA)-Class II-IV, with resting heart rate superior or equal to 75

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

3570

Participant exclusion criteria

1. Does not meet inclusion criteria
2. Investigators should follow the Summary of Product Specifications (SmPC) of Procoralan®, which include the following contraindications:
2.1. Hypersensitivity to the active substance or to any of the excipients
2.2. Resting heart rate below 60 beats per minute prior to treatment
2.3. Cardiogenic shock
2.4. Acute myocardial infarction
2.5. Severe hypotension (< 90/50 mmHg)
2.6. Severe hepatic insufficiency
2.7. Sick sinus syndrome
2.8. Sino-atrial block
2.9. Unstable or acute heart insufficiency
2.10. Pacemaker dependent
2.11. Unstable angina
2.12. Atrioventricular (AV) block of 3rd degree
2.13. Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os, josamycin, telithromycin), Human immunodeficiency virus (HIV) protease inhibitors (nelfinavir, ritonavir) and nefazodone
2.14. Pregnancy, lactation

Recruitment start date

19/04/2012

Recruitment end date

31/07/2012

Locations

Countries of recruitment

Germany

Trial participating centre

Servier Deutschland GmbH
München
80687
Germany

Sponsor information

Organisation

Servier Deutschland GmbH (Germany)

Sponsor details

Elsenheimerstr. 53
Munich
80687
Germany
+49 (0)89 5709501
martin.kuehn@de.netgrs.com

Sponsor type

Industry

Website

http://www.servier.com/

Funders

Funder type

Industry

Funder name

Servier Deutschland GmbH (Germany)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes